Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Botox for groin pain? small study explores new treatment

NCT ID NCT03496649

Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether injecting botulinum toxin A (Dysport) into the groin muscles could relieve chronic pain from adductor tendinopathy (pubalgia) in people who didn't get better with rest, anti-inflammatories, or physical therapy. Only 4 participants were enrolled before the study was stopped early. The goal was to see if this approach is worth studying further in larger trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Botulinum toxin A (Dysport) injection
What this could lead to
If this approach works, it could offer a new pain relief option for people with stubborn groin tendon pain that hasn't improved with standard treatments.
What could go wrong
This was a very small, early feasibility study that was terminated early, so results are limited. It's not yet proven to be safe or effective for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

4 people

The number who actually took part.

Started

May 2019

Finished

Jan 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patient 18 to 65 years old * Patient with episode of adductor tendinopathy, refractory to appropriate medical treatment lasting 3 months * Tendinopathy confirmed by clinical investigation, echography and MRI. * Patient naïve to intramuscular botulinum toxin injections * Patient able to self-evaluate pain on a VAS * Intensity of exercise-induced pain \> 5 on a VAS of 10 * Patient able to provide a signed informed consent freely for the study protocol and data collection Exclusion Criteria: * Subject participating or having participated in the last 3 months in another study which could interfere with the objective of the study * Neuralgia * Acute muscle injury * Progressive disease at the time of inclusion * Anticoagulant treatment: heparin administered with an electrical syringe or AVK therapy with effective doses Exclusion criteria related to Dysport injection (botulinum toxin type A) : * Known hypersensitivity to botulinum toxin type A or to any of the components in the formulation (20% human albumin solution, lactose monohydrate) * Subject with a significant deficit of clinical or subclinical neuromuscular transmission (myasthenia or Lambert-Eaton syndrome) * Treatment that directly or indirectly interferes with neuromuscular transmission (aminoglycosides, curare, anticholinesterase, aminoquinoline, cyclosporine, etc.) * Previous surgery with curarisation less than a month ago * History of neuromuscular disorders * Pregnant or breastfeeding woman * Women of child-bearing potential not using contraceptive methods during the study duration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Groin injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease of the tendon

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Groin injury Tendinopathy

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.